Moneycontrol Be a Pro
Get App
SENSEX NIFTY
YOU ARE HERE >  Moneycontrol Markets > Announcements PharmaceuticalsAnnouncement - AstraZeneca
AstraZeneca
BSE: 506820NSE: ASTRAZENISIN: INE203A01020

25th-Sep-2019 18:00Source: BSE

AstraZeneca Pharma - Astrazeneca Pharma India Limited Receives Import And Market Permission In Form 45 (Marketing Authorization) From Drugs Controller General Of India (DCGI) For FDC Of Dapagliflozin 10Mg + Saxagliptin 5Mg Film Coated Tablets (QTERN

This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets.

The receipt of this Import and Market permission paves way for the launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®) in India, subject to the receipt of other related statutory approvals and licenses.

FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).

More Announcements on:

1 2 3 4 5 Next >>
Sections
Follow us on
Available On